Cusatuzumab in CD70+ Relapsed/Refractory Cutaneous T-Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma
Cancer 2022 Mar 01;128(5)1004-1014, N Leupin, PL Zinzani, F Morschhauser, S Dalle, M Maerevoet, JM Michot, V Ribrag, F Offner, M Beylot-Barry, H Moins-Teisserenc, K Zwaenepoel, K de Winne, M Battistella, A Hultberg, D Gandini, M Moshir, J Jacobs, T Delahaye, A Khan, P Zabrocki, K Silence, L van Rompaey, C Borg, G Motta, F Melle, A Calleri, P Pauwels, H de Haard, S Pileri, M BagotFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.